Place and role of plasma purification technologies in treatment of severe forms of granulematosis with polyangiitis in ICU


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

ANCA-associated systemic vasculitis is characterized by overproduction of ANCA autoantibodies with specificity for myeloperoxidase or proteinase-3, affecting small and medium-sized vessels with the development of necrotizing vasculitis. Pathogenetic therapy includes the use of glucocorticosteroids, cytostatics, and monoclonal antibodies. In case of the development of life-threatening conditions, however, individual approaches to treatment should be used; drug therapy should be combined with extracorporeal methods: hemodialysis, therapeutic plasma exchange and double filtration plasmapheresis in the optimal combination for the patient and the optimal time of their use.

Full Text

Restricted Access

About the authors

Maria S. Vetsheva

Sechenov University

Email: rimsho@mail.ru
Dr. Sci. (Med.), Professor; Professor at the Department of Anesthesiology and Emergency Medicine, Faculty of General Medicine Moscow, Russia

Olga L. Podkorytova

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: o-podkorytova@yandex.ru
Cand. Sci. (Med.), Head of the Intensive Care Unit № 2 Moscow, Russia

Karina E. Loss

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: karina1512@mail.ru
Intensivist at the Intensive Care Unit № 2 Moscow, Russia

Oleg N. Kotenko

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: olkotenko@yandex.ru
Cand. Sci. (Med.); Head of the Moscow Scientific and Practical Center for Nephrology and Transplanted Kidney Pathology; Chief External Expert in Nephrology of the Moscow Healthcare Department Moscow, Russia

References

  1. Kain R., et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat. Med. 2008;14:1088-1096.
  2. Roth A.J., et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J. Am. Soc. Nephrol. 2012;23:545-555.
  3. Van der Woude F., Rasmussen N., Lobatto S., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425-429.
  4. Stegeman C.A., Cohen Tervaert J.W., Sluiter W.J., et al. Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener’s granulomatosis. Ann. Intern. Med. 1994;120:12-17.
  5. Popa E.R., Stegeman C.A., Abdulahad W.H., et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener’s granulomatosis. Rheumatol. (Oxford). 2007;46(6): 1029-1033.
  6. Millet A., Pederzoli-Ribeil M., Guillevin L., Witko-Sarsat V., Mouthon L. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group. Ann. Rheum. Dis. 2013; 72(8):1273-1279.
  7. Ball G.V., Bridges Jr.S.L. Ed Vasculitis. New York: Oxford University Press. 2002;1-4:34-45.
  8. Hunder G.G., Arend W.P., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthr. Rheum. 1990;33:1065-1067.
  9. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposalof an international consensus conference. Arthr. Rheum. 1994;37:187-192.
  10. Haynes B.E. Vasculitis: pathogenic mechanisms of vessel damage. In: Inflammation: basic principles and clinical correlates, 2nd edition (ed. J.I. Gallin, L.M.S.R. Golgstein). New York: Raven Press 921-941.
  11. Новиков П.И., Моисеев С.В. Рекомендации Британского ревматологического общества. Британской ассоциации ревматологов по лечению АНЦА-ассоциированных васкулитов у взрослых. Клин. фармакология и терапия. 2014;23(5):97-104.
  12. Watts R.A., Lane S.E., Bentham G. Scott DGI Epidemiology of systemic vasculitis - a 10-year study. Arthr. Rheum. 2000;43:422-427.
  13. Jennette J, Falk R., Bacon P., Basu N., et al. Revised International. Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthr. Rheum. 2012;65:1-11.
  14. Van Daalen E., Ferrario F, Noël L. H., et al. Twenty-five years of RENHIS: a history of histopathological studies within EUVAS. Nephrol. Dial. Transplant. 2015;30:31-36.
  15. Yates M., Watts R., Bajema I., et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 2016;75(9):1583-1594. doi: 10.1136/annrheumdis2016-209133.
  16. Fujimoto S., Watts R., Kobayashi S., et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibodyassociated vasculitis between Japan and the UK. Rheumatol. 2011;50:1916-1920.
  17. Бекетова Т.В. АНЦА-ассоциированный системный васкулит. Нефрология. Национальное руководство. Гл. ред. Н.А. Мухин. М., 2014.
  18. Ntatsaki E., Watts R.A., Scott D.G. Epidemiology of ANCA-associated vasculitis. Rheum. Dis. Clin. North Am. 2010;565: 447-461.
  19. Бекетова Т.В. АНЦА-ассоциированные системные васкулиты. Под ред. акад. РАНЕ.Л. Насонова. М., 2014.
  20. Бекетова Т.В. Асимптомное течение поражения легких при гранулематозе с полиангиитом (Вегенера). Научно-практическая ревматология. 2014;52(1):102-104.
  21. Booth A., Harper L., Hammad T., et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 2004;820:717-271.
  22. Shlomchik M.J. et al. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 2001;200:147-153.
  23. Voswinkel J., Mueller A., Kraemer J.A., et al. B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions. Gross Ann. Rheum. Dis. 2006;1200:859-864.
  24. Gross W.L. Immunopathology and newtherapeutic considerations in ANCA-associated vasculitides. Autoimmun. Rev. 2004;120:47-48.
  25. Harper L., Savage С. Pathogenesis of ANCA-associated systemic vasculitis. J. Pathol. 2000;190:149-159.
  26. Wiik A. Clinical and pathophysiological significance of anti-neutrophil cytoplasmic autoantibodies in vasculitis syndromes. Mod. Rheumatol. 2009;19:590-599.
  27. Finkielman J.D., Merkel P.A., Schroeder D., et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann. Intern. Med. 2007;147:611-619.
  28. Luqmani R., Bacon P., Moots R., Janssen B., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994; 87:671-678.
  29. Flossmann O., Bacon P, de Groot K., et al. Development of comprehensive disease assessment in systemic vasculitis. Ann. Rheum. Dis. 2007;66:283-292.
  30. Mukhtyar C., Lee R., Brown D. et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann. Rheum. Dis. 2009;68(12):1827-1832. doi: 10.1136/ard.2008.101279.
  31. Bhamra K., Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr. Rheumatol. Rep. 2012;14(6):494-500. doi: 10.1007/s11926-012-0291-1.
  32. Mukhtyar C., Guillevin L., Cid M., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 2009;68:310-317.
  33. Taylor S.R., Salama A.D., Joshi L., et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthr. Rheum. 2009;60(5):1540-1547.
  34. Бекетова Т.В., Александрова Е.Н., Новоселова Т.М. и др. Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014;52(2):147-158.
  35. Hebert L.A., Alvarado A., Rovin B. Rituximab or Azathioprine Maintenance in ANCA-Associated Vasculitis. N. Engl. J. Med. 2015;372:385-387.
  36. Merkel P.A. et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J. Rheumatol. 2011;38(7):1480-6. doi: 10.3899/jrheum.110276.
  37. Pagnoux C., Hogan S., Chin H., et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyassociated small-vessel vasculitis: Comparison of two independent cohorts. Arthr. Rheum. 2008;58:2908-2918. doi: 10.1002/art.23800.
  38. Буряк. И.С., Волков К.Ю., Юркин А.К., Жигулина А.И. Опыт применения 2 генно-инженерных биологических препаратов в лечении гранулематоза с полиангиитом. РМЖ. Ревматология. 2016;3:204-208.
  39. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010;363(3):221-232.
  40. Jones R.B., Tervaert J.W.C., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 2010;363(3):211-220.
  41. Caroti L., Cirami C.L., Di Maria L., et al. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: A case series. BMC. Nephrol. 2019;20(1):1-6.
  42. Chanouzas D., McGregor J.A.G., Nightingale P., et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: A multi-center retrospective cohort study. BMC. Nephrol. 2019;20(1):1-8.
  43. Walsh M., Merkel P., Peh C., et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. Published on-line 2020. doi: 10.1056/NEJMoa1803537.
  44. Jayne D.R., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. JASN. 2007;18:2180-2188.
  45. Schwartz J., Padmanabhan A., Aqui N., et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J. Clin. Apher. doi: 10.1002/jca. 31:149-162 (2016) American Society for Apheresis.
  46. Jayne D.R.W., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 2007;18:2180-2188.
  47. Ward D.M. Conventional apheresis therapies: a review. J. Clin. Apher. 2011;26(5):230-238.
  48. Gregersen J.W., Kristensen T., Krag S.R., et al. Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin. Exp. Rheumatol. 2012;30(1 Suppl. 70):39-47.
  49. Chen Y., Yang L., Li K., et al. Double Filtration Plasmapheresis in the Treatment of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis with Severe Renal Failure: A Preliminary Study of 15 Patients. Ther. Apher. Dial. 2016;20(2):183-188.
  50. Klemmer P.J., Chalermskulrat W., Reif M.S., et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with Small-Vessel vasculitis. Am. J. Kidney Dis. 2003;42:1149-1453.
  51. Бекетова Т.В. Европейские (EULAR/ERA-EDTA) рекомендации по диагностике и лечению АНЦА-ассоциированных системных васкулитов -2016. Научно-практическая ревматология. 2017;55(1):12-13.
  52. Wijngaarden de Lind van R.A.F., Hauer H.A, Wolterbeek R., et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J. Am. Soc. Nephrol. 2006;17(8):2264-2274.
  53. Буланов Н.М., Моисеев С.В., Новиков П.И. и др. Поражение почек при различных вариантах АНЦА-ассоциированного васкулита. Клин. Фармакол. Тер. 2016;5:23-9
  54. Томилина Н.А., Бирюкова Л.С., Фролова Н.Д. и др. Клиникоморфологическая характеристика и прогноз разных гистоморфологических вариантов быстропрогрессирующего гломерулонефрита, ассоциированного с АНЦА васкулитом. Нефрология и диализ 2017;19(4):466-477
  55. Guillevin L., Pagnoux C., Seror R. et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Med. 2011;90:19-27.
  56. Ward D.M. Conventional apheresis therapies: a review. J. Clin. Apher. 2011;26(5):230-238.
  57. Chan I.S., Ginsburg G.S. Personalized medicine: progress and promise. Ann. Rev. Genomics Hum. Genet 2011;12:217-244.
  58. Reddy P.J., Jain R., Paik Y.K., et al. Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology. Curr. Pharmacogenom. Person Med. 2011;9(1):67-75.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies